However, effective complications management can improve the rate of success.
INTRODUCTION
V arious surgical techniques have been proposed for treatment of refractory glaucoma such as mitomycin C, augmented trabeculectomy and the use of glaucoma drainage devices [1] [2] . The use of glaucoma drainage devices has increased dramatically in the past 20y. The number of the aqueous shunt implantations performed annually has risen from 2356 in 1994 to 12 012 in 2012 according to a recent analysis of US Medi Care database [2] [3] . Different kinds of glaucoma drainage devices have been used as an alternative to the standard filtering surgery or cyclodestructive procedures in refractory glaucoma [4] [5] [6] .
Indications include eyes with refractory glaucoma, such as neovascular glaucoma, uveitic glaucoma, glaucoma in aphakia and pseudophakia and eyes that have previously failed filtering operation [5] . The Ahmed glaucoma valve (AGV; New World Medical Inc., Rancho Cucamonga, California, USA) was introduced into market in 1993. It is a restrictive type of glaucoma devices that prevent postoperative hypotony [7] . Several studies on the success rate of AGV had been reported a number of complications involving the tube have been reported following insertion, such as tube blockage, retraction, exposure, malposition as well as more serious complications like hypotony, choroidal effusion, choroidal hemorrhage, cataract, retinal detachment and diplopia [2, [8] [9] [10] . However, long-term glaucoma in Mansoura Ophthalmic Center, Mansoura University, Egypt, during the period from May 2007 to September 2011. The study was approved by the Institutional Research Board of the Mansoura Faculty of Medicine and was performed in accordance with the ethical standards laid down in the Declaration of Helsinki with confidentiality of patients' records. Inclusion criteria included patients with increased intraocular pressure (IOP) >21 mm Hg that was not responsive to maximal medical treatment after failed glaucoma surgery. All patients included in this study attended for regular followup visits in our clinic. All the operations were performed by the same surgeon (Elhefney E). The valve used was either S2 or S3 model according to the age of the patient. Surgical Technique Fornix based conjunctival flap was performed in the superior temporal quadrant. The sclera was exposed. The tube was primed using balanced salt solution.
The plate was fixed to the sclera at a distance of 8-10 mm from the limbus using two 7/0 prolene sutures. A scleral flap 4 mm×4 mm was created and the tube was inserted into the anterior chamber after being trimmed with the bevel up through a pathway created at the limbus using 23 or 25-gauge needle in a plane parallel to the iris. In children, if scleral patch graft was available, no scleral flap was performed. A 9/0 prolene mattress suture was sutured to the sclera for more fixation of the tube. The conjunctiva was opposed using 6/0 vicryl sutures. At the end of the surgery, subconjunctival cefazoline and dexamethasone were injected. The postoperative regimen included topical ciprofloxacin 0.3 mg/mL four times daily for one week and 1% prednisolone acetate eight times daily for one week, with subsequent tapering over one month, dictated by the level of postoperative inflammation. Anti-glaucoma medications were added when required if the IOP increased >21 mm Hg. Patients were examined daily in the 1wk, weekly in the 1, 3, 6mo and 1y postoperatively then yearly till 5y after the surgery. at the end of follow-up time (P<0.001, Wilcoxon rank-sum test). The mean preoperative and postoperative glaucoma medications were 2.64±0.59 and 1.81±0.4 respectively (P=0.04, Wilcoxon rank-sum test) at the last follow-up (Table 3) . Postoperative outcomes in different patients groups at the end of follow-up were recorded in Table 4 . Outcomes of overall patients in different follow-up period were demonstrated in Table 5 . At the end of follow-up period (5y), the percentage of success including both complete and qualified success was encountered in 77.5%. Of those, 39 eyes (31.5%) had complete success, 57 eyes (46.0%) had qualified success.
Postoperative complications were recorded in Table 6 . Encapsulated AGV was the most common late complication encountered postoperatively (51 eyes, 41.1%). Other complications included cataract in 9 eyes (7.25%), recessed tube in 8 eyes (6.45%) following AGV implantation in eyes with pediatric glaucoma. Four eyes of them were managed by AGV exchange with supra-tenon flexible AGV implantation. Of 18 eyes were successfully managed by needling with MMC application followed by anti-glaucoma medication. Deroofing of the encapsulated plate was successfully performed in 20 eyes (Figure 1 ). The other 4 eyes were managed by second AGV implantation in the superior or superior nasal quadrant of the globe (Figure 2 ). Totally 13 eyes with encapsulated plate showed failure after deroofing (IOP>21 mm Hg with maximum anti-glaucoma medications). Postoperative interventions to achieve the success criteria and causes of failure are demonstrated in Tables 7 and 8 respectively. DISCUSSION AGV, with a restriction flow mechanism, is a shunt device that is used in treatment of refractory glaucoma either as a primary surgical option or after failure of conventional filtration procedures. The overall success rate varies among different types of glaucomas, ranging from 60% to 100% at one year of follow-up in different case series with different follow-up periods [12] . However, prior glaucoma surgery increases the risk of failure of glaucoma implantation by more than three-fold [13] . In addition, the use of antimetabolites increases the long-term side effects particularly in pediatric patients [14] . To best of our knowledge, most of the studies regarding the success of glaucoma drainage devices were carried in the developed countries, with limited numbers of published studies in the developing countries with small sample size and variable follow-up duration [11, [15] [16] . In the current study, we retrospectively reviewed the results of AGV implantation in cohort of Egyptian patients with refractory glaucoma with long-term follow-up. In our study, AGV implant was able to decrease the mean preoperative IOP from 37.2±6.8 mm Hg to 16.4±4.1 mm Hg at 12mo and 19.2±5.2 mm Hg at 5y postoperatively. Moreover, reduction of the number or frequency of medications to control IOP is considered as a parameter of success in refractory glaucoma. In our study, glaucoma medications were reduced from 2.64±0.59 preoperatively to 1.81±0.4 at the end of follow-up period. This observation concurs with Souza et al [12] and Wishart et al [10] who reported a significant reduction in the number of medications following AGV implantation. Zarei et al [11] reported IOP decrease from a mean preoperative value of 30.8±5.6 mm Hg to 20±6.4 mm Hg with a mean follow-up time of 40.50mo after AGV implantation. Similar results were demonstrated in various studies carried in Kuwait [15] , Saudi Arabia [16] , and Oman [17] in which AGV implantation reduced IOP and the number of medications required to control refractory glaucoma. In our study, the overall success rate (complete and qualified) varies among different types of glaucoma, with average of 89.5% at 1y, 81.5% at 3y and 77.4% at 5y of follow-up. The failure occurred in 28 eyes (22.6%) at the end of follow-up. Similar results were reported by Smith et al [18] , with complete success of rate of 10.5% and guarded success rate of 73.7% in cases that underwent AGV surgeries during a mean follow-up time of 38.8mo. However, failure rate in the current study is a little bit higher than recorded by tube versus trabeculectomy (TVT) study [19] as all included eyes in our study were eyes with failed previous incisional surgeries that could increase the risk of failure of AGV implantation as reported before [12] . On the other hand, our results were somewhat better than recorded in other studies. Lai et al [20] reported IOP control in 73.8% of 65 Chinese eyes during follow-up time ranging from 6-37mo following AGV implantation, the absolute success was 43.1% and qualified success was 30.7%. Souza et al [12] reported that approximately 50% of AGV implantation in refractory glaucoma were successful after 5y of follow-up. Zarei et al [11] reported 70% success rate with adjuvant anti-glaucoma medications within a mean follow-up of 40mo after AGV implantation in 28 eyes with age ranging from 7-75y. The differences on types of races of the study population, type of implants, etiology of glaucoma, and the duration of follow-up, could explain the variations in success rate between studies. The major cause of failure was excessive fibrosis and encapsulated cyst formation (41.1%) which were consistent with the other studies [23] [24] . The incidence of bleb encapsulation has been recorded to be between 40% and 80% with the AGV implantation in different studies of refractory glaucoma [5] [6] .
Needling with MMC injection was performed in 18 eyes of our studied patients (14.5%). Deroofing of the encapsulated plate with cyst excision was successfully performed in 20 eyes (16.1%) followed with adjuvant anti-glaucoma treatment. Capsule excision after failed Molteno surgery was examined by Valimaki et al [24] , they reported a 52% success rate with revision alone (IOP less than 22 mm Hg), whereas 42% required a second tube shunt for IOP control. Lai et al [20] reported encapsulated bleb in 16 eyes (24.6%). Totally 10 eyes received needling with MMC and 6 eyes received cyst excision. The IOP was successfully controlled in 14 eyes of them [20] . Cataract formation was the second most common complication that reported in 9 eyes (7.25%) in our study. Similarly, Zarei et al [11] reported tube iris touch with cataract in 10.8%.
Recessed tube occurred in 8 eyes (6.5%) with recurrent congenital glaucoma most probably due to increased globe size during growth. They were managed with AGV replacement using flexible implant in the supra-tenon space. Tube exposure was recorded in 6 eye (4.8%) with pediatric glaucoma mostly due to recessed conjunctiva and lack of sclera patch graft at the time of AGV implantation, which was managed, by sclera patch graft and conjunctival advancement. Lai et al [20] reported exposure of the tube due to erosion of the episcleral patch graft in 3.1% and extrusion of the implant in 6.2% of 65 eyes underwent AGV implantation. In our study, extrusion was recorded in only 2 eyes (1.6%). Quaranta et al [25] achieved the outcomes improvement of AGV surgery by usage of, bovine pericardial graft to cover valve without using suture. This enabled to reduce both mean IOP as well as the number of medication in refractory glaucoma patients. In a study carried by Zarei et al [11] focal corneal decompensation was demonstrated in 10.7% due to corneal tube touch. Chen et al [26] reported corneal decompensation in 2.3% and implant extrusion in 1.4% of 221 eyes following AGV implantation. In the current study, focal corneal tube touch with was recorded in only 6 eyes (4.8%) due to anterior tube migration. However, such problem was managed successfully by tube revision before occurrence of corneal decompensation. Different studies on AGV implantation outcome for refractory glaucoma reported frequencies of hypotony varying from 9.4% to 12% [27] [28] . Severe hypotony requiring removal of the AGV occurred in only 2 of the 124 operated eyes in our series (1.6%). Although endophthalmitis is a rare complication after glaucoma drainage implant (GDI) surgery, the exact rate is not known [29] . Several retrospective studies of GDIs have included a single case or a few cases of endophthalmitis resulting in rates ranging from 0.8% to 6.3% [3, [29] [30] [31] [32] [33] [34] . We reported only 2 eyes with endophthalmitis of 124 studied eyes (1.6%). Conjunctival dehiscence over the GDI tube seems to represent a major risk factor for endophthalmitis [33] . A limitation of this study is that it is a retrospective with inclusion of only subjects with previously failed filtering surgeries and refractory glaucoma. We tried to minimize this by using all of the AGV patients who qualified for the study during last 5y and operated by the same surgeon. Another limitation is lack of homogeneity of the study population, which was eliminated by studying larger sample size with longer follow-up than reported in most of the published literatures. In conclusion, refractory glaucoma with failed previous incisional glaucoma surgery is very difficult situation to manage. AGV is effective in treating refractory glaucoma with increasing the rate of success by effective management of complications. Encapsulated cyst formation was the most common complication, which can affect successful IOP control without anti-glaucoma medication.
